Effective Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorders Compared With Azathioprine and Mycophenolate

Yang Yang1#, Lifeng Chen2#, Lei Wu3, Jiarui Yao1, Na Wang4, Xiaqing Su1, Dongmei Li1, Lina Han1, Weiping Wu1, Dehui Huang3*, Tianyu Jiang4*, Zhenfu Wang1*

1Department of Neurology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, China.
2Department of Neurosurgery, The First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, China.
3Department of Neurology, The First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, China.
4Department of Rehabilitation Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, China.

*These authors have contributed equally to this work.

*Corresponding authors: Zhenfu Wang email: wwp301@163.com, Tianyu Jiang email: jty301@126.com and Dehui Huang email: huangdehui@gmail.com
Supplement Figure 1: the changes of EDSS (A,C) and ARR(B,D) after AZA treatment either in seropositive anti-AQP4 antibody patients(A,B) or seronegative anti-AQP4 antibody patients(C,D)(P<0.05). EDSS: expanded disability status scale, ARR: annualized relapses rate, AZA: azathioprine.
Supplement Figure 2: the changes of EDSS (A,C) and ARR(B,D) after MMF treatment either in seropositive anti-AQP4 antibody patients (A,B) or seronegative anti-AQP4 antibody patients (C,D) (P<0.05). EDSS: expanded disability status scale, ARR: annualized relapses rate, MMF: mycophenolate mofetil.